Routine immunohistochemical assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in breast cancer holds great significance due to the critical prognostic and therapeutic implications of these biomarkers [3]. This evidence concerns the gene PGR and breast cancer.